EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Oncology, Womens’s health - No. 684 Imprimer
Silvia de Sanjose et al on behalf of the Retrospective International Survey and HPV Time Trends Study Group (The Lancet Oncology, Early Online Publication, 18 October 2010 doi:10.1016/S1470-2045(10)70230-8) provided novel data about the worldwide genotype distribution in patients with invasive cervical cancer. They collected confirmed cases of invasive cervical cancer of epithelial origin from 38 countries (n=14 249 women). HPV detection was done by use of PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation line probe assay. Sequence analysis was done to characterise HPV-positive samples with unknown HPV types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions. 10 575 cases of invasive cervical cancer were included in the study, and 8977 (85%) of these were positive for HPV DNA. The most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 91%,(95% CI 90-92). HPV types 16 and 18 were detected in 71% of invasive cervical cancer. HPV types 16, 18, and 45 were 94%, of cervical adenocarcinomas. Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types (50·0 years [49·6-50·4], 48·2 years [47·3-49·2], 46·8 years [46·6-48·1], and 55·5 years [54·9-56·1], respectively).
 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн